SCHEMBL2234446

SCHEMBL2234446

O=C(/C=C/C(=O)OC12CCC(CC(Oc3ccc(Cl)cn3)C1)N2Cc1cccnc1)OC12CCC(CC(Oc3ccc(Cl)cn3)C1)N2Cc1cccnc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.41
OPRK1 P41145 3/20 0.41
OPRM1 P35372 1/20 0.37
FAAH O00519 1/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35
HCRTR1 O43613 2/20 0.34
HCRTR2 O43614 2/20 0.34
MMP1 P03956 1/20 0.34
CYP17A1 P05093 1/20 0.34
CYP19A1 P11511 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MDM2 Q00987 2/20 0.34
P2RX7 Q99572 1/20 0.34
IP6K1 Q92551 1/20 0.34
CACNA1I Q9P0X4 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2236893 0.92 KCNH2 (0.39) KCNH2OPRK1OPRM1HCRTR1HCRTR2
SCHEMBL2238212 0.87 OPRK1 (0.39) KCNH2OPRK1OPRM1HCRTR1HCRTR2
SCHEMBL2239158 0.84 KCNH2 (0.44) KCNH2OPRK1OPRM1
Fumaric Acid SCHEMBL2234450 0.77 KCNH2 (0.59) KCNH2OPRK1OPRM1
Fumaric Acid SCHEMBL2234437 0.77 KCNH2 (0.59) KCNH2OPRK1OPRM1
SCHEMBL2238309 0.74 KCNH2 (0.57) KCNH2OPRK1OPRM1
SCHEMBL2236838 0.74 KCNH2 (0.41) KCNH2OPRK1OPRM1
Fumaric Acid SCHEMBL2238216 0.69 KCNH2 (0.55) KCNH2OPRK1OPRM1
Fumaric Acid SCHEMBL2238207 0.69 KCNH2 (0.55) KCNH2OPRK1OPRM1
SCHEMBL8109748 0.68 SCN9A (0.41) KCNH2OPRK1FAAHCHRNB2CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989470-B2 3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2011-08-02 US disclosed
US-20100190821-A1 3,8-SUBSTITUTED 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2010-07-29 US disclosed
US-7713990-B2 3,8-substituted 8-AZA-bicyclo[3.2.1]octane derivatives and their use as monomine neurotransmitter re-uptake inhibitors NEUROSEARCH A/S (DK) 2010-05-11 US disclosed
US-20080004252-A1 3,8-Substituted 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monomine Neurotransmitter Re-Uptake Inhibitors NEUROSEARCH A/S (DK) 2008-01-03 US disclosed
EP-1838705-A2 3,8-SUBSTITUTED 8-AZA-BICYCLO [3.2.1] OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2007-10-03 EP disclosed
WO-2006075004-A2 3, 8 - SUBSTITUTED 8-AZA-BICYCLO[3.2.1] OCTANE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS NEUROSEARCH A/S (DK) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190821-A1 3,8-SUBSTITUTED 8-AZA-BICYCLO[3.2.1]OCTANE DERIVATIVES AND THEIR USE AS MONOMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS SLC18A2, SLC18A3, SLC6A2 KCNH2 1080/4885OPRK1 185/4885OPRM1 87/4885
US-20080004252-A1 3,8-Substituted 8-Aza-Bicyclo[3.2.1]Octane Derivatives and Their Use as Monomine Neurotransmitter Re-Uptake Inhibitors SLC18A2, SLC18A3, SLC6A2 KCNH2 1080/4885OPRK1 185/4885OPRM1 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.